- Merck and Moderna announced that combining an experimental personalized mRNA vaccine with Keytruda successfully prevented melanoma from spreading or returning after surgery.
- The Phase 3 trial involved over 1,000 patients, marking a major milestone in the use of mRNA technology for personalized cancer treatment.
- Following the announcement, Moderna stock soared over 120% while Merck shares climbed more than 10% in morning trading, according to CNBC.
- Melanoma is the deadliest form of skin cancer, with over 8,500 deaths and 112,000 new cases estimated in the United States this year.
- Researchers are currently expanding trials for the experimental mRNA vaccine to target other cancer types, including lung, bladder, and renal cell carcinoma.
IN FULL
